Uromodulin in Rheumatoid Arthritis
Märksõnad
Abstraktne
Kirjeldus
Uromodulin, also known as Tamm-Horsfall protein, is a protein abundantly excreted in the urine in healthy individuals. It is synthesized in the thick ascending limb of Henle (TALH) and the early distal convoluted tubule. Its biologic function is still obscure; however, some experimental studies indicated that it might serve as an important urinary defense factor against bacterial colonization and stone formation.
There are controversial publications on the frequencies of urinary tract infections and nephrolithiasis in patients with mutations of uromodulin gene. Deposition of mutated uromodulin in the urinary system may lead to tubular cell dysfunction and apoptosis. These alterations may subsequently cause tubular atrophy and interstitial fibrosis . Moreover, the release of abnormal uromodulin after apoptosis through basolateral secretion may elicit an immune response which may give rise to an immune-mediated tubulointerstitial nephritis .
Uromodulin can activate the other components of the immune system and may modulate the inflammatory and immune responses through different mechanisms .
Experimental studies yielded that uromodulin negative mice displayed splenomegaly with infiltration of white pulp by macrophages and increased levels of TNF-α and interleukin-1 . Rheumatoid arthritis is a systemic autoimmune condition that may eventually result in the joint damage, disability and premature mortality.
Kuupäevad
| Viimati kinnitatud: | 04/30/2019 |
| Esmalt esitatud: | 05/03/2019 |
| Hinnanguline registreerumine on esitatud: | 05/30/2019 |
| Esmalt postitatud: | 06/02/2019 |
| Viimane värskendus on esitatud: | 05/30/2019 |
| Viimati värskendus postitatud: | 06/02/2019 |
| Õppe tegelik alguskuupäev: | 04/30/2017 |
| Eeldatav esmane lõpetamise kuupäev: | 04/30/2018 |
| Eeldatav uuringu lõpetamise kuupäev: | 05/31/2018 |
Seisund või haigus
Faas
Käerühmad
| Arm | Sekkumine / ravi |
|---|---|
| ra patients The diagnosis of RA was based on the criteria developed by the American College of Rheumatology and European League Against Rheumatism (ACR/EULAR) in 2010 [8]. A drug history was obtained from every patient. All non-steroidal anti-inflammatory medications and disease-modifying antirheumatic drugs prescribed during the year before enrollment in the study were recorded. criteria included systemic diseases (renal failure, hepatic insufficiency, diabetes mellitus, other collagen vascular diseases, history of smoking and consumption of alcohol.In order to eliminate the possibility of any systemic disease therefore we choose that our control group as young. | |
| healthy control healthy person, similar population |
Abikõlblikkuse kriteeriumid
| Õppimiseks sobivad vanused | 18 Years To 18 Years |
| Uuringuks kõlblikud sood | All |
| Proovivõtumeetod | Probability Sample |
| Võtab vastu tervislikke vabatahtlikke | Jah |
| Kriteeriumid | Inclusion Criteria: - Patients who diagnosed of rheumatoid arthritis as criteria of ACR/EULAR 2010. - All patients age range is 18-80 years. Exclusion Criteria : - Renal failure - Hepatic insufficiency - Diabetes mellitus - Other collagen vascular diseases, - History of smoking and consumption of alcohol |
Tulemus
Esmased tulemusnäitajad
1. Patients with rheumatoid arthritis [1 day]
2. A.joint involvement [1 day]
3. B.Serology (at least 1 test result is needed for classification) [1 day]
4. C.Acute-phase reactants (at least 1 test result is needed for classification) [1 day]
5. D.Duration of symptoms [1 day]
6. Uromodulin measure [1 day]
Sekundaarsed tulemusmõõdud
1. CKD-EPI (Chronic Kidney Disease Epidemiology Colloboration) [1 day]
2. MDRD (Modification of Diet in Renal Disease) [1 day]
3. Urea measure [1 day]
4. Creatinine measure [1 day]
5. Sedimantation measure [1 day]
6. pH measure [1 day]
7. Microalbuminuria measure [1 day]
